CATX 241220 5.00P (CATX241220P5000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CATX241220P5000

Watchlist

1.90
+1.85+3700.00%

15min DelayClose Nov 21 16:00 ET

1.90High1.50Low

Intraday

5D
Daily

News

Cautious Optimism: Justin Walsh's Buy Rating on Perspective Therapeutics Amidst Mixed Trial Results
TipRanks23minutes ago · Ratings
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga16:06 ET
Promising Potential in Perspective Therapeutics' VMT-alpha-NET Program Amid Market Hesitations
TipRanks12:35 ET
Perspective Therapeutics Pursuing Dose Escalation Study in Neuroendocrine Tumors
MT NewswiresNov 21 10:56 ET
Express News | Perspective Therapeutics Shares Are Trading Lower. The Company Announced Initial Results From Its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET
BenzingaNov 21 10:41 ET
Express News | Perspective Therapeutics Inc : Wedbush Cuts Target Price to $11 From $20
ReutersNov 21 10:23 ET

Comments

Stock_Drift

Nov 15 16:17

After Hours Ticks. 5:16pm 11/15🦌

$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊

Trytosaveabit

Nov 15 15:13

Watching! Note the dates!

$Perspective Therapeutics (CATX.US)$ Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium t...

Jaguar8

Nov 15 15:08

NEWS

$Perspective Therapeutics (CATX.US)$
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and eff...

70162843

Nov 15 14:58

$Perspective Therapeutics (CATX.US)$ no one wants their shares lol

Abela

Oct 11 09:17

$Perspective Therapeutics (CATX.US)$ thank you 🙏🙏🙏